Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in …Sacramento Bee… VGX-100 (a human antibody against VEGF-C) as a treatment for solid tumours, in particular glioblastoma and colorectal cancer, as well as for 'front …
Weekly Analysts' Ratings Changes for Alexion Pharmaceuticals, Inc. (ALXN)LocalizedUSA… development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the th…
Mother's never-ending hope paves way for son's recoveryCatholic News AgencyRight now, he visits the hospital every other month for a biopsy to look for signs of cellular rejection of his new heart. Wary of germs, Jennifer has four bottles of wh…
Local woman breathing new life after lung transplantAhwatukee Foothills NewsSo far, she hasn't shown any signs of transplant rejection, a good sign that the transplant has been successful. While she won't live a "normal" life, since s…
The AgeFrom the Big Bang to nanotechnologyThe AgeTheir research, published in the journal Proceedings of the National Academy of Sciences, or PNAS, opens the way to reducing transplant rejection in all organs as well as new ways to fight hepatitis and …
Rigel says two of its lead product candidates R548 and R333 enters into …pharmabiz.comThe company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidat…
CHKM, ALXN, RDDY, HOLI, FSIN, EXAR are Stocks to Watch on Jan-6 AfternoonBeacon Equity ResearchTheir market cap is 13.73B . Alexion Pharmaceuticals, Inc is engaged in the discovery, development and delivery of biologic therapeutic products and life-thr…
Globe and MailIsotechnika makes executive changesGlobe and Mail“This change is designed to allow Dr. Foster to continue to focus firmly on Phase 3 development activities of the company's leading product candidate, voclosporin, for the prevention …
Isotechnika Announces Changes to Senior Management and Board of DirectorsMarketWatch (press release)This change is designed to allow Dr. Foster to continue to focus firmly on Phase 3 development activities of the Company's leading product candidate…
TrovaGene to Buy MultiGen's CLIA Lab to Bolster Infectious Disease TestingGenetic Engineering NewsThe firm says it has achieved proof-of-principle for candidate markers in infectious disease testing, cancer detection and monitoring, organ transplan…